Abstract
In this research, HEK293 cells were subjected to a hypoxia-reoxygenation (HR) model in vitro. The protective effects of hesperidin (Hes) were evaluated by assessing the cell viability value and the mitochondrial cardiolipin content. In contrast to the HR-subjected cell group, Hes (concentrations of 4-32 μM) significantly improved the HEK293 cell viability value (p<0.05). Moreover, the group of cells pretreated with Hes (concentrations of 4 and 8 μM) before the HR phase had higher cardiolipin content than the group of disease model cells but not treated with Hes. These preliminary results showed that Hes could be a potential compound in protecting HEK293 cells and their mitochondria against HR injury.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
